Altogen Labs extensive biotechnology and pharmacology research services include the following:
- PRE-CLINICAL RESEARCH SERVICES
- Pharmacology and toxicology testing: IC50 for Tumor Cell Lines
- Xenograft Animal Service: Immunocompromised NOD/SCID Mice
- Therapeutic RNAi development: targeted siRNA, qPCR assays
- Liposome Encapsulation services: siRNA, miRNA, DNA, proteins
- ELISA and Cell-Based Assay Development (Cell Cycle, Viability)
- Apoptosis Assay: Caspase-3 and Caspase-7 Cell Line Screen
- RNAi Consulting Services: technology delevopment & evaluation
- GENERATION OF STABLE CELL LINES
- CELL BANKING SERVICES
- RNA INTERFERENCE (RNAi) SERVICES
- In vivo siRNA delivery and tissue-targeting
- siRNA Transfection and RNAi Cell-based Library Screening
- Generation of Tet-inducible RNAi gene knockdown cell lines
- RNAi screen pathway analysis: siRNA and microRNA library
- RNAi manufacturing and CRO services
- PCR Cloning: shRNA-encoding vector construction
- In Vivo Stable siRNA and microRNA - Chemical modification
- Quantitation sh/siRNA-induced knockdown by qRT-PCR and WB
- Reporter gene assays and Stable RNAi cell line development
- Genome-wide siRNA and microRNA high-throughput screens
- Stable RNAi Cell Line Generation: Stable Gene Knockdown
- siRNA liposome encapsulation service
- Transient (siRNA) and stable (shRNA) transfection services
- BIOLOGY LABORATORY CRO SERVICES
- BIOREMEDIATION SERVICES
- BACTERIA ID 16S SEQUENCING
In vivo siRNA delivery and tissue-targeting
In Vivo siRNA Delivery and Tissue Targeting
RNAi experiments in animals can be difficult and expensive, and present numerous technical challenges. Altogen Labs offers complete A-to-Z RNAi services, including in vivo siRNA development, chemical modification of siRNA (to increase stability in serum), siRNA encapsulation into liposome, siRNA tissue targeting, qRT-PCR assay to measure siRNA accumulation, biodistribution, functional target mRNA knockdown, reduction of protein expression, off-target effects, immune system response, and many other RNAi in vivo services.
RNAi-induced gene silencing is used to study gene function in cultured cells. However, this approach does not allow for critical evaluation of gene function within the whole organism. The application of RNAi in vivo may present many technical challenges due to siRNA stability, delivery efficiency, and tissue targeting. Altogen Labs has developed methods to prevent siRNA degradation in serum and increase delivery efficiency to target organs, enhancing the effect (phenotype) induced by siRNA in vivo.
Two basic methods are adapted for RNAi use in vivo: administration of small interfering RNA (siRNA) and administration of plasmid DNA and viral vectors, which express a short hairpin RNA (shRNA) that is subsequently processed into active siRNA in vivo. In general, viral-based shRNA vectors provide the highest delivery efficiency in vivo, but are time-consuming to construct and have significant immunogenicity problem.
Altogen Labs provides complete in vivo siRNA development services including encapsulation and tissue-targeted siRNA delivery. Multiple siRNA administration routes local and systemic are possible: intravenous, intraperitoneal, intranasal, intratumoral, intratracheal, intradermal, intramuscular, intrathecal, intracerebellar, and intravascular perfusion.
see also: In vivo siRNA delivery and tissue-targeting | siRNA Transfection and RNAi Cell-based Library Screening | Generation of Tet-inducible RNAi gene knockdown cell lines | RNAi screen pathway analysis: siRNA and microRNA library | RNAi manufacturing and CRO services | PCR Cloning: shRNA-encoding vector construction | In Vivo Stable siRNA and microRNA - Chemical modification | Quantitation sh/siRNA-induced knockdown by qRT-PCR and WB | Reporter gene assays and Stable RNAi cell line development | Genome-wide siRNA and microRNA high-throughput screens | Stable RNAi Cell Line Generation: Stable Gene Knockdown | siRNA liposome encapsulation service | Transient (siRNA) and stable (shRNA) transfection services